- Tags: dry eye
Research
Bausch + Lomb unveils 2025 state of dry eye survey results
Building on 2024 findings, latest results indicate a need for more patient education to dispel ongoing misconceptions surrounding dry eye.
Pipeline
Stuart Therapeutics reports initial phase 3 DED eye drop data
Results on ST-100 (vezocolmitide), a collagen mimetic peptide, support its role as a fast-acting resolution for dry eye signs and symptoms.
Research
Botox injections may actually help treat DED
Botox injections significantly improved key disease parameters, supporting its potential clinical utility.
Pipeline
Aldeyra resubmits reproxalap NDA for dry eye (again)
Company includes new phase 3 dry eye crossover data in updated submission package; an FDA acknowledgement response is expected within 30 days.
Products
CSI Dry Eye Software releases update for AI-based clinical platform
Version 6.0 of the cloud-based software features an intuitive dashboard and automated reminders for clinicians diagnosing and treating DED patients.
Events
Dry Eye Foundation to host DC advocacy days in July
Nonprofit prepares to kick off its first-ever dry eye patient advocacy day and symposium at the Capitol to raise awareness of the impact of DED on everyday life
Pipeline
FDA clears IND for Zhaoke Ophthalmology's CsA ophthalmic gel
Clearance paves the way for a new phase 3 trial to evaluate CsA 0.05% for its safety and efficacy among moderate-to-severe DED patients—with plans for an eventual NDA submission.
Research
TFOS releases DEWS III Diagnostic Methodology report
Authors of the latest Dry Eye Workshop report call for a simplified patient screening questionnaire, a revised symptomatic DED definition, and updates to risk factors.
Products
Bausch + Lomb launches two new eye drops to Blink portfolio
Now available at most U.S. retailers, the latest additions to this specialty product line includes Blink Nourish Lubricating and Blink Boost Lubricating eye drops.
Products
Scope Health debuts OPTASE cloud-based meibographer and digital solution
Newly-acquired technologies feature a portable device with HD imaging as well as a customizable, HIPAA-compliant cloud server for dry eye clinics.
Products
FDA approves Alcon's TRYPTYR (acoltremon ophthalmic solution) 0.003% for DED
The prescription-based eye drop is the first that stimulates corneal nerves to directly address tear deficiency; company plans for a Q3 2025 U.S. launch.
Pipeline
FDA clears Selagine's immunoglobulin DED drops for phase 2 trial
IND approval supports clinical development and evaluation of the anti-inflammatory and immunomodulatory biologic drug, potentially the first of its kind in the U.S.
Research
Air pollution exposure leading to more ocular disease cases among adults
Myopic eyes demonstrated increased risk of ocular disease with exposure to air pollution.
Products
Scope Health brings eyelid health to forefront with new PF OPTASE LIFE eye cream
Experts share tips for ensuring eyelid hygiene and health of all patients as Scope launches its newest product for those with dry eye: the OPTASE LIFE Sensitive Eye Daily Renewal Cream.
Pipeline
Aldeyra to resubmit reproxalap NDA following positive phase 3 data
Company reports statistically significant findings supporting the potential DED treatment after last month’s FDA-issued CRL.
Pipeline
Palatin reports symptom resolution phase 3 data for DED eye drop
Responder analyses indicate PL9643 achieved statistically significant complete symptom clearing across multiple endpoints starting at 2 weeks and increasing to week 12.
Pipeline
Long-term data finds acoltremon 0.003% increases tear production in DED
Presented at ASCRS, phase 3 COMET-4 results show AR-15512 provides a rapid onset and sustained improvement over 12 months.
Business
CSI Dry Eye Software selects new CEO
Eye care industry executive Ken Barbet takes the helm as the AI-based dry eye management platform seeks to help ECPs standardize and deliver customized treatment.
Products
TearRestore launches eyelid serum for digital eye strain
Available over the counter, the WINQ Eyelid Serum is clinically studied and supported in reducing partial blink rates by 50% after just one application.
Research